Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Sepura, ReNeuron, Angel Bio ...

Wed, 16th May 2012 15:18

Sepura, the developer and supplier of TETRA digital radios, has acquired 3T Communications, a supplier of TETRA infrastructure, for an initial cash consideration of 8m euros. The final price could increase by up to 5m euros, depending on 3T's trading performance. Austrian firm 3T designs and implements small to mid size TETRA systems predominantly for the commercial sector, including enterprise customers such as Shell, RWE, Bayer and BMW. The acquisition is expected to be earnings enhancing to Sepura for the current financial year and beyond.Electrical component supplier e2v technologies has agreed the sale of its non-core businesses, for a total cash consideration of £14.7m, to a newly formed company, SGX Sensortech, backed by Baird Capital Partners. The non-core businesses comprise: e2v Scientific Instruments, based in High Wycombe; the industrial gas sensing business based at e2v's Chelmsford facility; and e2v micro-sensors SA based in Neuchetel Switzerland. They provide a range of professional sensing products for x-ray spectroscopy and gas sensing for automotive and environmental safety applications.ReNeuron, the Surrey based stem cell developer, has signed a cell manufacturing contract with Angel Biotechnology, a bio-pharmaceutical contract manufacturer, to perform drug product manufacturing services as part of the PISCES Phase I clinical trial of ReNeuron's ReN001 stem cell therapy for stroke victims. The remaining dose cohorts in the current study are expected to complete treatment within the next twelve months, and the company maintains its belief that the study will be ready for application for phase two during the course of next year.Arden Partners, an institutional stockbroking company, has revealed that trading during the six months ended April 30th has been better than anticipated with revenues and profitability ahead of budget. Since the year end the company has increased the number of brokerships to 34 and this number is expected to grow in the medium term. The average market capitalisation of its clients is now £195m. Performance in the second half of the year will depend on market conditions, which given the situation in Europe dictates a need for some caution, the firm warned. The company intends to return to the dividend list from the interim period. Yell, a digital services provider, has acquired Moonfruit, the UK's leading DIY website and online shop builder, for £18m, a part of its programme of creating a local eMarketplace. The firm was purchased using Yell's existing cash reserves. Retention bonuses of as much as £5.2m will be paid to key Moonfruit management after two years, provided that they remain exclusively employed by Yell. In a statement Yell said: "The deal is a significant move in Yell's ongoing transformation from its established position in providing print and online advertising for small and medium-sized enterprises (SMEs) to become a leader in the emerging local eMarketplace." Source BioScience, a diagnostics and genetic analysis business, has enjoyed a period of sustained growth and development during the first three months of 2012. Revenue saw a double digit percentage increase compared with the same period last year, boosted by significant progression of LifeSciences' DNA sequencing services and Healthcare's cervical cancer screening business. Trading was in line with management expectations and the group remains in a robust financial position with £1.7m of cash at the end of March 2012 (31 December 2011: £1.1m).NR
More News
12 Sep 2018 14:44

ReNeuron pleased with progress on several therapy fronts

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its trading on Wednesday, as investors gathered for the firm's annual general meeting, announcing that following recent co-ordinating ethics committee approval, the first clinical site has now been initiated in the US Phase IIb study with its CTX cell therapy candidate for stroke disability.

Read more
12 Sep 2018 13:54

ReNeuron Expects To Enroll First Patient For Stroke Study Shortly

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday it expects to enroll the first patient in its stroke disability study "shortly".The company said that the first clinical

Read more
5 Jul 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 6 July SVM UK Emerging FundFull Year Results Monday 9 July GroupHalf

Read more
19 Apr 2018 13:17

ReNeuron Wins GBP1.5 Million Grant For Stem Cell Therapy Development

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it is the "lead" industry participant in a new GBP1.5 million grant from the UK's innovation agency Innovate grant has to

Read more
3 Apr 2018 13:29

Portugal looks to renewables as March output tops mainland power demand

LISBON, April 3 (Reuters) - For the first time in at least four decades, Portugal's monthly renewable energy production in March exceeded power demand

Read more
26 Mar 2018 15:53

ReNeuron Now Expects hRPC Stem Cell Trial Data In First Half Of 2019

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it has decided to adjust the number of clinical sites for its CTX stem cell therapy candidate study, and now expects

Read more
5 Dec 2016 11:06

ReNeuron's first half revenues supported by new drug developments

(ShareCast News) - ReNeuron, an AIM-listed UK based developer of cell-based therapeutics, saw first half revenues double due to a series of successful drug trials. Revenues were £22,000 for the six months ended 30 September 2016 up from £11,000 in the first half of 2015. During the period, the grou

Read more
4 Dec 2016 14:45

Sunday share tips: ReNeuron, Clipper Logistics, RM Secured Direct Lending

(ShareCast News) - Shares of ReNeuron are for brave investors only, said the Sunday Times' Inside the City column. The stem cell pioneer is scheduled to publish the results of second-phase clinical trials of its potential stroke paralysis treatment alongside its interim results on Monday. ReNeuron's

Read more
6 Sep 2016 11:38

ReNeuron reports positive progress in clinical trials

(ShareCast News) - UK-based developer of cell-based therapeutics ReNeuron Group provided a trading update ahead of its annual general meeting on Tuesday. The AIM-traded firm reported that all patients have been treated in the PISCES II Phase II clinical trial of its CTX cell therapy candidate for pa

Read more
7 Jul 2016 09:37

ReNeuron Annual Loss Widens As Product Trials Ramp Up

Read more
4 Jul 2016 15:16

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
13 Jun 2016 07:58

ReNeuron Completes Phase II Stroke Therapy Trial Patient Recruitment

Read more
9 Jun 2016 08:55

ReNeuron Selects Glioblastoma Multiforme As First Clinical Target

Read more
8 Jun 2016 08:36

ReNeuron Progressing Blindness Candidate Through Phase I/II Trial

Read more
15 Mar 2016 09:52

ReNeuron Says First Patient Treated For Retinitis Pigmentosa

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.